A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)
Phase of Trial: Phase III
Latest Information Update: 22 Apr 2018
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms GALACTIC-HF
- Sponsors Amgen
- 15 Feb 2018 According to a Cytokinetics media release, company expect to complete enrolling patients in approximately one year.
- 26 Oct 2017 According to a Cytokinetics media release, the company expects continued enrollment of patients with chronic heart failure in GALACTIC-HF trial throughout 2017.
- 19 Sep 2017 According to a Cytokinetics media release, first patient ij Japan has been dosed.